These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511 [TBL] [Abstract][Full Text] [Related]
7. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M; Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668 [TBL] [Abstract][Full Text] [Related]
8. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan. Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760 [TBL] [Abstract][Full Text] [Related]
9. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. Vemuri N; Michelis MF; Matalon A BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172 [TBL] [Abstract][Full Text] [Related]
10. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. How PP; Anattiwong P; Mason DL; Arruda JA; Lau AH Hemodial Int; 2011 Jan; 15(1):95-9. PubMed ID: 21138519 [TBL] [Abstract][Full Text] [Related]
11. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients. Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759 [TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients. Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508 [TBL] [Abstract][Full Text] [Related]
13. Clinical experiences of bixalomer usage at our hospital. Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of continuous oral administration of lanthanum carbonate over 24 months. Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509 [TBL] [Abstract][Full Text] [Related]
15. Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate. Hyodo T; Kawakami J; Mikami N; Wakai H; Ishii D; Yoshida K; Iwamura M; Hida M; Kurata Y Ther Apher Dial; 2014 Jun; 18 Suppl 1():14-7. PubMed ID: 24953761 [TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate: a postmarketing observational study of efficacy and safety. Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T; J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966 [TBL] [Abstract][Full Text] [Related]
18. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. Noto L J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905 [TBL] [Abstract][Full Text] [Related]
19. [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]. Arenas MD; Malek T; Álvarez-Ude F; Gil MT; Moledous A; Reig-Ferrer A Nefrologia; 2010; 30(5):522-30. PubMed ID: 20613851 [TBL] [Abstract][Full Text] [Related]
20. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Finn WF; Joy MS; Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]